New pill targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase trial is testing a new daily pill called NDI-219216 for people with advanced solid tumors that have not responded to standard treatments. The study will first check safety and side effects, then look at whether the drug can shrink tumors. About 134 participants w…
Phase: PHASE1, PHASE2 • Sponsor: Nimbus Wadjet, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC